analgesic/diarrhea

This application claims priority from European Patent Application No. 05 001 967.8 filed Jan. 31, 2005, incorporated herein by reference in its entirety. FIELD OF THE INVENTION The present invention is directed to the prevention, reversal and medical treatment of lower urinary tract dysfunction

FIELD OF THE INVENTION The present invention is directed to delta-opioid receptor modulators. More particularly, the present invention is directed to 4-[aryl(8-azabicyclo[3.2.1]octan-3-yl)]aminobenzoic acid derivatives which are delta-opioid receptor modulators useful as effective

Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to describe more fully the state of the art to which this invention pertains. BACKGROUND OF THE

Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to describe more fully the state of the art to which this invention pertains. BACKGROUND OF THE

Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to describe more fully the state of the art to which this invention pertains. BACKGROUND OF THE

Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to describe more fully the state of the art to which this invention pertains. BACKGROUND OF THE

BACKGROUND OF THE INVENTION Alpha adrenergic receptors are plasma membrane receptors which are located in the peripheral and central nervous systems throughout the body. They are members of a diverse family of structurally related receptors which contain seven putative helical domains and transduce

FIELD OF THE INVENTION This invention relates generally to alleles of the human mu opioid receptor gene, along with products derived from such alleles. Also included herein are methods of diagnosing various susceptibilities using such alleles and determining treatment for certain diseases based upon

FIELD OF THE INVENTION This invention relates generally to alleles of the human mu opioid receptor gene, along with products derived from such alleles. Also included herein are methods of diagnosing various susceptibilities using such alleles and determining treatment for certain diseases based upon

FIELD OF THE INVENTION The present invention is directed to delta-opioid receptor modulators and methods for use thereof. More particularly, the present invention is directed to benzamidine derivatives which are delta-opioid receptor agonists or antagonists and methods for use thereof. BACKGROUND OF

FIELD OF THE INVENTION The present invention is directed to delta-opioid receptor modulators and methods for use thereof. More particularly, the present invention is directed to substituted aminoquinuclidine compounds which are delta-opioid receptor modulators, agonists or antagonists and methods

The present invention relates to delta-opioid receptor agonists/antagonists. More particularly, the present invention relates to 4-[aryl(piperidin-4-yl)]aminobenzamides which are delta-opioid receptor agonists useful as analgesics. BACKGROUND OF THE INVENTION WO9723466 to Plobeck N. et al.,

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT The research and development of the invention described below was not federally sponsored. BACKGROUND OF THE INVENTION WO 97/23466 describes compounds as having an analgesic effect of a general and one preferred formula: ##STR00001## WO

FIELD OF THE INVENTION The present invention is directed to compounds useful as delta-opioid and mu-opioid receptor modulators. More particularly, the present invention is directed to 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives useful as delta-opioid or mu-opioid receptor

This application is a 371 of PCT/JP95/02236 filed Nov. 1, 1995, published as WO96/14293 May 17, 1996. TECHNICAL FIELD The present invention relates to novel 1,3-dialkylurea derivatives having a hydroxyl group which have inhibitory effects on endopeptidase 24.11 and are useful as therapeutic agents